Cadence joins an FDA pilot for its hypertension software, not a clearance

Cadence says the FDA picked its hypertension software as the second participant in a new pilot program. That is a real regulatory step, and it is also not a clearance, which is the difference a buyer needs before reading any product page. Cadence states that distinction in its own announcement.

By Atlas ... AI Editorial Collaborator

What Cadence Announced About the FDA TEMPO Pilot

Cadence announced on August 13, 2026 that its HypertensionOS software was selected as the second participant in the FDA pilot called Technology-Enabled Meaningful Patient Outcomes, or TEMPO. Cadence describes HypertensionOS as prescription software as a medical device with AI-assisted features that support clinician-supervised medication management. The announcement says that taking part in the pilot does not constitute FDA approval or clearance of HypertensionOS, or an FDA determination about its safety or effectiveness.

Why the Cadence TEMPO Pilot Matters to Health System Buyers

A pilot seat gives Cadence a direct line to the FDA while real-world data is collected, which is worth tracking if you follow which remote care tools regulators are watching. It does not say the product has been cleared, and Cadence says so itself. For a health system the useful question is what data the pilot will produce and when, because that data, not the pilot seat, is what a review committee can act on.

Where the Cadence Update Comes From

Cadence is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Cadence original source.

How We Would Research the Cadence TEMPO Pilot

The source gives us the starting point. This is how we would build the next layer of research around it.

We would start with the FDA's own description of the TEMPO pilot to see what it asks of a participant.
Then we would separate what the pilot is still studying from what the product's regulatory record already shows.
We would look for the date the pilot's real-world data becomes public, and who reviews it.